March 7, 2018 07:30 AM EST

Flanked by rivals and skeptics, Esperion flips positive data on first PhIII for a potentially game-changing cholesterol pill

John Carroll

Editor & Founder

Esperion $ESPR is rolling out its first positive data set from a slate of pivotal late-stage studies of its LDL-lowering drug bempedoic acid this morning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Flanked by rivals and skeptics, Esperion flips positive data on first PhIII for a potentially game-changing cholesterol pill

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron makes $80M obesity deal with Hansoh

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Updated: Omada Health rose 21% in its public market debut

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Flanked by ri­vals and skep­tics, Es­pe­ri­on flips pos­i­tive da­ta on first PhI­II for a po­ten­tial­ly game-chang­ing cho­les­terol pill

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Flanked by rivals and skeptics, Esperion flips positive data on first PhIII for a potentially game-changing cholesterol pill